Abbott wins expanded CE mark for Navitor TAVI system, reports updated TEER guidelines
August 29, 2025
Abbott (NYSE: ABT)+
announced today that it received CE mark for an expanded indication for its Navitor TAVI system.
Abbott (NYSE: ABT)+
announced today that it received CE mark for an expanded indication for its Navitor TAVI system.
Medtronic (NYSE: MDT)+
announced today that it received FDA approval for the expanded redo-TAVR indication of its Evolut system.
Cartherics, a biotech company developing off-the-shelf immune cell therapies focusing on high-impact women’s diseases, with lead programs in ovarian cancer and endometriosis, has announced the granting of a patent for ‘Method for Providing Immune Cells with Enhanced Function’ by the Chinese Patent Office.
Ciliatech announced today that it received CE mark approval for its Intercil uveal spacer, an eye implant for treating glaucoma.
Airiver Medical announced today that it received FDA investigational device exemption (IDE) for its pulmonary drug-coated balloon (DCB).
The liquid biopsy test has been developed by experts in cancer genomics.
Brightonix Imaging announced today that its flagship Pharos positron emission tomography (PET) scanner received FDA clearance.
Abbott (NYSE: ABT)+
announced today that it received CE mark for its Esprit BTK everolimus-eluting resorbable scaffold system.
The CIRRUS PathFinder tool is available via licensing in the new software update.
PERTH, Australia, Aug. 21, 2025 /PRNewswire/ — Artrya Limited (ASX: AYA) (Artrya or the Company), a medical technology company commercialising its Salix® AI-powered cloud platform, for the near real time, point of care assessment and management of coronary artery disease, is pleased to announce it has received 510(k) clearance from the U.S. Food and Drug Administration (the FDA) for Artrya’s proprietary, Salix® Coronary Plaque module.